Medical Condition News

RSS

Heartburn can cause cancer: New guide for patients

Every day, an estimated 25 million American adults suffer from heartburn. Some experts believe that 40 percent of adults experience heartburn every month. Despite these staggering statistics, few people understand the real risk that Heartburn can cause Cancer.

6 Aug 2012

Wellcome Trust grants £1.6 million Translation Award for development of more effective radiotherapy

The Wellcome Trust has awarded a £1.6 million Translation Award to a research team led by the University of Lincoln to develop more effective radiotherapy treatment for thousands of cancer sufferers by providing unique monitoring and imaging for patients receiving proton therapy.

6 Aug 2012

New Translational Oncology Program at University of Michigan

The University of Michigan Comprehensive Cancer Center is harnessing its expertise in basic science research to speed the translation into clinical trials and new treatment opportunities for cancer patients.

6 Aug 2012

Older adults with head trauma over a weekend more likely to die

A Johns Hopkins review of more than 38,000 patient records finds that older adults who sustain substantial head trauma over a weekend are significantly more likely to die from their injuries than those similarly hurt and hospitalized Monday through Friday, even if their injuries are less severe and they have fewer other illnesses than their weekday counterparts.

6 Aug 2012

Mutations in Ras gene alone may not cause tumours

Despite a huge amount of research effort, the molecular mechanisms that underlie the transition from a "normal" cell to a cancerous cell are only poorly understood. After the discovery of the first cancer-causing genes or oncogenes and the finding that they are mutated forms of normal cellular genes, it was widely believed that a single mutation was enough to cause cancer.

6 Aug 2012

Human-derived breast cancer xenografts allow revolution in individualized cancer care

Cell cultures are homogeneous. Human tumors are not. A University of Colorado Cancer Center study recently published in the journal Breast Cancer Research and Treatment reports the development of human-derived estrogen-positive (ER+) breast cancer models that retain their heterogeneity, allowing researchers to more accurately test drugs for this disease.

6 Aug 2012

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $48.2 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer researchers.

6 Aug 2012

Previously uncharacterized protein dramatically influences inflammation

A UNC-led team of scientists describes the function of a previously uncharacterized protein that dramatically influences inflammation.

6 Aug 2012

Death risk increases with 'excessive' CABG surgery waiting times

In the Canadian healthcare system, patients with longer than recommended waitlist times for coronary artery bypass graft (CABG) surgery are at increased risk of dying in the hospital, reports Medical Care.

6 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

6 Aug 2012

IOF, PAOS invite medical professionals to attend CME-accredited meeting in Jordan

The International Osteoporosis Foundation (IOF) and the Pan Arab Osteoporosis Society (PAOS) invite medical professionals to attend their joint meeting at the King Hussein Bin Talal Convention Centre, Dead Sea, Jordan, from September 27 to October 1, 2012.

6 Aug 2012

FDA grants 510(k) clearance to VICTUS Femtosecond Laser Platform

Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH, a leading ophthalmology laser company, announced today that the VICTUS Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration.

6 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Common anti-angina drug may help protect the heart against carbon monoxide poisoning

An international research team, led from the University of Leeds, has found that a common anti-angina drug could help protect the heart against carbon monoxide poisoning.

6 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.

6 Aug 2012

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Medical Condition News

Heartburn can cause cancer: New guide for patients

Wellcome Trust grants £1.6 million Translation Award for development of more effective radiotherapy

New Translational Oncology Program at University of Michigan

Older adults with head trauma over a weekend more likely to die

Mutations in Ras gene alone may not cause tumours

Human-derived breast cancer xenografts allow revolution in individualized cancer care

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

Previously uncharacterized protein dramatically influences inflammation

Death risk increases with 'excessive' CABG surgery waiting times

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

IOF, PAOS invite medical professionals to attend CME-accredited meeting in Jordan

FDA grants 510(k) clearance to VICTUS Femtosecond Laser Platform

New research center to expedite study of gene transfer approach

Common anti-angina drug may help protect the heart against carbon monoxide poisoning

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News